Table 1.

Clinical characteristics of the participants with Parkinson’s disease.

Patients		Age (years)	More affected side	MDS-UPDRS-III akinesia score	On/off state during recording	LEDD (mg/dL)	Disease duration (years)
ID	Sex
1	Female	68	Right	8	On	625	5
2	Female	76	Right	5	On	0	1
3	Male	73	Left	13	On	0	4
4	Male	54	Left	5	On	340	3
5	Female	72	Left	4	On	37.5	30
6	Female	69	Left	7	On	175	4
7	Male	75	Left	17	On	400	8
8	Male	69	Left	12	Off	1406	15
9	Female	70	Left	9	On	891.5	10
10	Female	52	Left	1	On	715	11
11	Female	72	Left	15	On	100	1
12	Male	69	Left	12	On	110	4
13	Male	54	Right	14	Off	1344.5	11
14	Female	68	Right	7	On	100	4
15	Male	63	Left	19	On	1037.5	7
16	Female	55	Right	20	Off	560	6
17	Male	64	Left	12	On	0	3
18	Female	69	Left	8	On	200	5
19	Female	72	Left	14	On	975	18
20	Male	52	Left	13	On	549	4
21	Male	53	Right	11	On	1081	18
22	Male	66	Left	14	On	752.2	8
23	Female	66	Left	21	Off	948	5

MDS-UPDRS-III akinesia score sum of akinesia-related scores on the Movement Disorder Society–sponsored revision of the Unified Parkinson’s Disease Rating Scale, part III; LEDD levodopa equivalent daily dose.